

ADMINISTRATION OF EYLEA® (aflibercept) 8 mg

Instructions for use and handling
of EYLEA 114.3 mg/mL in patients
with nAMD or DMO¹

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).¹

For UK healthcare professionals only.

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) can be accessed [here](#) or via the QR code located on the last page of this document.


The EYLEA 114.3 mg/mL glass vial is for one-time use in one eye only. Discard the unused portion. Extraction of multiple doses from a single vial may increase the risk of contamination and subsequent infection.

Do not use if the package or its components are expired, damaged or have been tampered with. Check the label on the vial to make sure you have the correct aflibercept strength.

The intravitreal injection should be performed with a 30 G × ½ inch injection needle.


EYLEA is intravitreal injection only. EYLEA must only be administered by a qualified healthcare professional experienced in administering intravitreal injections.

STEP 1: INSPECT THE VIAL AND REMOVE THE VIAL CAP




Visually inspect the vial and contents and remove the plastic cap. Disinfect the outer part of the rubber vial stopper. An assistant should carry out this step (*in the images the injector is shown with white gloves and the assistant is shown with grey gloves*). Do not use the vial if particulates, cloudiness or discoloration are visible.

STEP 2: ATTACH THE FILTER NEEDLE




Using aseptic technique, attach the filter needle supplied in the carton to a 1 mL sterile Luer Lock syringe.

STEP 3: INSERT NEEDLE INTO VIAL



Insert the filter needle until it is completely inserted into the vial and the needle tip touches the bottom of the vial.


STEP 4: SLOWLY DRAW UP THE SOLUTION



Withdraw all the vial contents into the syringe, keeping the vial in an upright position, slightly inclined to ease complete withdrawal and ensuring the bevel of the needle is submerged in the liquid. Ensure the plunger rod is drawn sufficiently back to completely empty the filter needle.


All steps must be carried out using aseptic technique

STEP 5: REMOVE THE FILTER NEEDLE




Unscrew and properly dispose of the filter needle. Do not use the filter needle for intravitreal injection.

STEP 6: ATTACH THE INJECTION NEEDLE




Firmly twist a 30 G x 1/2 inch injection needle (not provided) to the Luer Lock syringe tip.

STEP 7: CHECK FOR AIR BUBBLES




Visually inspect the contents of the syringe. If bubbles are present, gently tap the syringe with your finger until the bubbles rise to the top.

STEP 8: ELIMINATE AIR BUBBLES AND EXCESS DRUG




EYLEA 8 mg uses 0.07 mL volume of EYLEA 114.3 mg/mL solution. Eliminate all air bubbles and expel excess drug by slowly depressing the plunger rod to align the base of the plunger dome with the 0.07 mL line on the syringe for the EYLEA 114.3 mg/mL vial.



Incorrect plunger position for 0.07 mL volume.

The syringe is now ready for intravitreal injection. Note that due to the viscosity of EYLEA 114.3 mg/mL, there may be some resistance when pushing the syringe plunger.

STEP 9: DISPOSE OF ANY UNUSED MEDICINAL PRODUCT OR WASTE MATERIAL IN ACCORDANCE WITH LOCAL REGULATIONS



Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.

Either click [here](#) or scan the QR code for prescribing information and adverse event reporting information.

For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.



**Scan the QR code below to discover more EYLEA 8 mg training resources.
Scanning this QR code will lead to promotional content aimed at UK
healthcare professionals.**



Reference

1. EYLEA 114.3 mg/mL Summary of Product Characteristics.

Abbreviations

DMO, diabetic macular oedema. nAMD, neovascular age-related macular degeneration.

© Bayer plc. ® Registered trademark of BAYER AG, Germany.

PP-EYL_8mg-GB-0344 | December 2024